Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Chronic Constipation
Interventions: Matching Placebo, Linaclotide; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 105
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 98 more

Conditions: Gastroparesis, Functional Dyspepsia, Vomiting Syndrome
Interventions: Temporary Gastric Electrical Stimulation; Device
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Atopic Dermatitis
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 12 more

Conditions: Defect of Articular Cartilage
Interventions: Hyalofast, Microfracture; Device · Procedure
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 18
States / cities: Tempe, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: Healthy Participants
Interventions: BMS-986322, BMS-986322 Placebo, famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Colorectal Neoplasms, Diarrhea
Interventions: PHY906; Drug
Lead sponsor: PhytoCeutica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: West Haven, Connecticut • New York, New York • Greenville, South Carolina

Conditions: Colonoscopy, Mass Screening
Interventions: Mailed educational brochure; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 628 participants
Timeline: 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: AV608; Drug
Lead sponsor: Avera Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Energy, Fatigue
Interventions: Recharge Placebo Control 1, Recharge Active Study Product 1, Recharge Active Study Product 2, Recharge Active Study Product 3; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Mild Alzheimer's Disease
Interventions: Allogeneic MSC, Placebo; Drug · Other
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Aventura, Florida • Delray Beach, Florida • Doral, Florida + 3 more

Conditions: HIV Infections
Interventions: IMVAMUNE (MVA-BN); Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more

Conditions: Healthy Volunteers
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Bilateral Ovarian Disease
Interventions: Anti adhesion agent; Biological
Lead sponsor: OMRIX Biopharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Pain
Interventions: Gabapentin, placebo; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 21 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Volunteers
Interventions: LY4178256, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Los Alamitos, California • Salt Lake City, Utah

Conditions: Type 1 Diabetes
Interventions: glargine insulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 19 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: ECG, Electrocardiography, Monitoring, Physiologic
Interventions: Chest-Worn ECG Monitoring Device; Device
Lead sponsor: Perin Health Devices; Industry
Eligibility: 22 Years to 90 Years
Enrollment: 255 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Woodland Hills, California

Conditions: Gastro-Oesophageal Cancer
Interventions: Regorafenib, Placebo; Drug · Other
Lead sponsor: Australasian Gastro-Intestinal Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more

Conditions: Achondroplasia
Interventions: TransCon CNP, Placebo for TransCon CNP; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Saint Paul, Minnesota + 5 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Emmanuelle Waubant, MD PhD; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: SLE
Interventions: Envudeucitinib, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 48
States / cities: Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more

Search by objective public record fields.

Trial of Linaclotide in Patients With Chronic Constipation

Controlled Trial of Gastric Electrical Stimulation in Children

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

HyaloFAST Trial for Repair of Articular Cartilage in the Knee

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

RCT of Mailed Brochure to Boost Adherence to Screening Colonoscopy

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

Radicle Recharge: A Study of Health and Wellness Products on Energy Levels and Other Health Outcomes

Lomecel-B Effects on Alzheimer's Disease

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil

Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy

A Study of LY4178256 in Healthy Participants

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Sexual Functioning Study With Antidepressants

Validation of Perin Health Patch ECG Monitoring Device Performance and Placement Accuracy

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults